Transforming growth factor beta reduces proprotein convertase subtilisin/kexin type 9 in the supernatant of hepatic stellate cells

Figure 3 Regulation of proprotein convertase subtilisin/kexin type 9 levels in LX-2 cells by cytokines, adipokines, and nuclear receptor agonists. A and B: Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels in LX-2 cells cultivated with tumor necrosis factor and interleukin-6. PCSK9 levels in the LX-2 cell supernatant after 24 hours of cultivation with 0 ng/mL, 0.2 ng/mL, 2 ng/mL, or 4 ng/mL tumor necrosis factor, 4 independent experiments (A); PCSK9 levels in the LX-2 cell supernatant after 24 hours of cultivation with 0 ng/mL, 5 ng/mL, 10 ng/mL, or 20 ng/mL interleukin-6, 4 independent experiments (B); C-E: PCSK9 levels during LX-2 cell cultivation with adipokines and chemerin isoform overexpression. PCSK9 levels in the LX-2 cell culture supernatant after 24 hours of cultivation with 0 μg/mL or 10 μg/mL adiponectin, 6 independent experiments (C); PCSK9 levels in the LX-2 cell culture supernatant after 24 hours of cultivation with 0 ng/mL, 4 ng/mL, 10 ng/mL, or 20 ng/mL leptin, 4 independent experiments (D); PCSK9 in the supernatant of LX-2 cells cultivated for 24 hours with overexpressed chemerin-155, chemerin-156, or chemerin-157 and in control transfected cells, 4 independent experiments (E); F-H: PCSK9 levels during LX-2 cell cultivation with nuclear receptor agonists. PCSK9 levels in the LX-2 cell culture supernatant after 24 hours of cultivation with 0 μmol/L, 1 μmol/L, and 2 μmol/L GW4064, 5 independent experiments (F); PCSK9 levels in the LX-2 cell culture supernatant after 24 hours of cultivation with 0 μmol/L, 5 μmol/L, and 10 μmol/L T0901317, 3 independent experiments (G); PCSK9 in the supernatant of LX-2 cells cultivated for 24 hours with 0 μmol/L, 7.5 μmol/L, and 15 μmol/L rosiglitazone, 3 independent experiments (H). PCSK9: Proprotein convertase subtilisin/kexin type 9; TNF: Tumor necrosis factor; IL: Interleukin; Chem: Chemerin.